



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

July 13, 2022

Brendan Smith
Chief Financial Officer
CRISPR Therapeutics AG
Baarerstrasse 14
6300 Zug
Switzerland

Re: CRISPR Therapeutics AG
Form 10-K for the fiscal year ended December 31, 2021
Filed February 15, 2022
File No. 001-37923

Dear Mr. Smith:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences